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Abstract
Summary We evaluated the relationship between bone mate-
rial strength index (BMSi) and fragility fractures, including
vertebral fractures. Our data showed that BMSi is low in all
fracture patients with low bonemass, independently of wheth-
er patients sustained a vertebral or a non-vertebral fracture.
Introduction Impact microindentation (IMI) is a new tech-
nique for the measurement of tissue level properties of cortical
bone in vivo. Previous studies showed an association between
BMSi and non-vertebral fractures, but an association with
vertebral fractures is still being debated. The objective of this
paper was to evaluate the relationship between BMSi and
different types of fragility fractures, including vertebral
fractures.
Methods In this cross-sectional study, we measured BMSi in
patients of both sexes with different types of fragility fractures
and low bone mass with the IMI method using the
Osteoprobe®. Vertebral fractures were diagnosed and graded
on lateral spine radiographs.
Results A total of 132 patients were included in the study, of
whom 101 patients (65 women) had sustained a low energy
fracture and 31 (mean age 57.7 ± 9.9 years) had no history or
radiological evidence for a fracture. Of the fracture patients,
53 (mean age 62.8 ± 8.3 years) had only non-vertebral frac-
tures (VF−/Fx+), 34 (mean age 62.8 ± 9.9 years) had vertebral
and non-vertebral fractures (VF+/Fx+), and 14 (mean age
64.7 ± 9.3 years) had only vertebral fractures (VF+/Fx−).
BMSi values, adjusted for age and BMD, were similar for
all three groups of fracture patients (78.9 ± 0.7, 78.3 ± 0.9,
and 78.4 ± 1.4, respectively; p = 0.866). BMSi values were not
associated with number or severity of vertebral fractures.
Conclusion Our data demonstrate that BMSi is low in fracture
patients with low bone mass, irrespective of whether they
sustained a vertebral fracture or a non-vertebral fracture.
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Introduction
Reference point indentation (RPI) is a technique to measure
cortical bone indentation properties in vivo and to potentially
assess bone mechanical properties. Currently available RPI
devices use two different methods to assess cortical bone re-
sistance to indentation namely cyclic microindentation (CMI,
Biodent) and impact microindentation with an easier to use
hand-held indenter (IMI, OsteoProbe), the latter being specif-
ically designed for in vivo use in humans and large animals
[1–3]. The principles, similarities, and differences as well as
results of clinical application of the two devices were recently
reviewed [4–6]. In a direct comparison of the two methods in
cadaveric human tibiae, Karim and colleagues reported that
results of measurements are weakly related indicating that
each device reflects different aspects of cortical bone indenta-
tion properties [7]. Although the exact properties of bonemea-
sured in vivo by microindentation need to be determined,
clinical studies with both devices demonstrated that the meth-
od could differentiate patient groups with increased fracture
risk from control groups independently of bone mineral den-
sity (BMD) values suggesting that the method measures as-
pects of bone fragility not captured by BMD.
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Initial application of CMI in humans showed that postmen-
opausal womenwith osteoporotic fractures (hip or vertebra) or
those with atypical femoral fractures had greater indentation
distances compared with controls, which were poorly related
with hip BMD [2, 8]. Clinical studies with IMI demonstrated
that the measured parameter bone material strength index
(BMSi) was significantly lower in postmenopausal women
with type 2 diabetes mellitus compared with healthy controls
in the presence of similar BMD values [9], and patients treated
with glucocorticoids showed significant deterioration of
BMSi within 7 weeks of starting treatment, before any chang-
es in BMD [10]. Our group also showed that despite similar
BMD values, BMSi values were lower in patients with fragil-
ity fractures compared with those without fractures [11].
The impact microindentation technique has recently been
used to examine the association between BMSi and vertebral
fractures, but results are conflicting. In a population-based
cohort of 211 older women with or without fractures, includ-
ing 58 women with vertebral fractures, there was no associa-
tion between BMSi values and prevalent vertebral fractures
[12]. In contrast, a preliminary communication of a study in
101 postmenopausal women (30 with vertebral fractures) re-
ported lower BMSi values in patients with fractures than in
healthy controls and a significant inverse relationship between
BMSi and severity of vertebral fractures [13].
The question raised by these studies is whether BMSi as
measured by IMI provides information on just cortical bone
fragility or on overall bone fragility. To address this question,
we expanded our previously reported cohort to specifically
examine the association between BMSi and different types
of fragility fractures, in particular those of the vertebrae.
Patients and methods
This was a cross-sectional study that evaluated BMSi in men
and women attending the outpatient clinic of the Center for
Bone Quality of the Leiden University Medical Center
(LUMC). The patients described in the current study include
those of our previous report of the comparison of BMSi
between patients with fragility fractures and those without
fractures [11]. The study design, inclusion and exclusion
criteria, and methodology used were previously described
[11] and are summarized below. The Medical Ethics
Committee of the LUMC approved the study and informed
consent was obtained from all patients.
Sequentially invited patients aged between 40 and 85 years
with low bone mass (osteopenia or osteoporosis), and no sec-
ondary osteoporosis or other metabolic bone disease were
invited to participate in the study. Other exclusion criteria
included serum 25-OH vitamin D concentrations ≤25 nmol/
l, current use of glucocorticoids, aromatase inhibitors, andro-
gen deprivation therapy, or chemotherapy or ever use of bone-
acting agents such as bisphosphonates or denosumab.
Fragility fractures were defined as any low-energy fracture,
excluding those of hands, feet, and skull. FRAX 10-year prob-
abilities for a major osteoporotic fracture and a hip fracture,
with and without femoral neck BMD, were calculated using
the FRAX algorithm [14]. Blood was collected for standard
laboratory investigations including calcium, creatinine, para-
thyroid hormone, and 25-OH vitamin D. BMD was measured
by DXA (Hologic QDR 4500), and conventional lateral radio-
graphs of the thoracic and lumbar spine were obtained.
Vertebral fractures were identified and graded according to
the semi-quantitative method of Genant by two of the authors
(F.M. and N.A.-D.) [15]. Kappa was 0.85.
BMSi was measured in all pat ients by impact
microindentation (IMI) [3, 5] on the midshaft of the right
tibia using a hand-held microindenter (OsteoProbe® RUO,
Active Life Scientific, CA, USA) by a single operator [11].
The patient is placed in a decubitus supine position with
the tibia in external rotation to orient the flat surface of the
medial tibia diaphysis in a horizontal position. The mea-
surement site is defined as the mean distance between the
distal apex of the patella and medial malleolus. Following
disinfection of the area and local anesthesia of the skin and
periosteum with Lidocaine 1%, the test probe is gently
inserted in the skin until the bone surface is reached. The
operator ensures that the test probe is placed perpendicu-
larly to the bone surface and classifies the measurements as
Bwell performed,^ Badequate,^ or Bpoorly performed^ after
the indentation and before checking the computer display
of the result. BPoorly performed^ measurements are usual-
ly due either to slipping of the test probe or to moving of
the subject’s leg and are discarded. After five adequate
measurements, as recommended [5], five additional mea-
surements are performed on a polymethylmethacrylate
(PMMA) calibration phantom. BMSi is calculated as 100
times the harmonic mean of the indentation distance in-
crease from impact into the PMMA material divided by
the average indentation distance increase from impact into
bone. As the probe indents the surface of the cortical bone
of the tibia, it induces a microfracture. The more easily this
occurs, the deeper the probe indents the bone, and thus, the
lower the BMSi is [3].
In 10 subjects, the measurement was repeated in the same
leg at sites 2 cm apart; mean (SD) of the two measurements
was 75.9 ± 5.7 and 76.6 ± 4.9, respectively. The intra-observer
coefficient of variation (CV) was 2.2%.
Statistical analysis
All data are expressed as mean ± SD unless otherwise stated.
Between-group differences in baseline characteristics were
assessed by Student’s t test, ANOVA, and Chi square test or
a Mann-Whitney U test or Kruskall-Wallis test for non-
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normally distributed variables. Post hoc analyses using
Bonferroni were performed to adjust for multiple comparisons
if required, and non-parametric post hoc analyses using
Kruskall-Wallis were performed to compare BMSi values be-
tween the three fracture groups and non-fracture controls.
Pearson’s or Spearman’s correlations were used to assess cor-
relations between patients’ parameters and BMSi. ANOVA
with BMSi as outcome variable, adjusted for age, was used
to compare BMSi values between patients with fractures and
those without fractures. The relationship between BMSi and
the severity of vertebral fractures was assessed by a linear
multiple regression model adjusted for age and femoral neck
BMD. A probability level of random difference of 0.05 was
considered significant. The SPSS software for Windows
(Version 23; SPSS Inc., Chicago, IL, USA) was used for sta-
tistical analysis of results.
Results
One hundred and thirty-two patients (64% women), 101 of
whom had sustained at least one fragility fracture, consented
to take par t in the study and underwent impact
microindentation, a median of 3.3 months after their most
recent fracture, Table 1. Mean age of the whole group was
61.8 ± 9.4 years, 76 patients (58%) had osteopenia, and 56
(42%) osteoporosis. Consistent with our previous findings, in
this larger cohort, we found that BMSi was inversely and
significantly related with age (r = −0.485, p < 0.001) and with
FRAX 10-year probability calculated with and without femo-
ral neck BMD (Spearman’s r = −0.313, p < 0.001, and
Spearman’s r = −0.356, p < 0.001, respectively). There was
no correlation between BMSi with any other patient charac-
teristic, laboratory, or BMD value. There was no difference in
BMSi values between women and men (79.7 ± 0.6 vs 80.0
0.8; p = 0.789). In the whole cohort of subjects with low bone
mass, patients with fractures had significantly lower age-
adjusted BMSi values than those without fractures
(79.0 ± 0.5 vs 82.5 ± 0.9; p = 0.001).
Fifty-three patients had only non-vertebral fractures (VF
−/Fx+), 34 had non-vertebral and vertebral fractures (VF+/
Fx+), and 14 had only vertebral fractures (VF+/Fx−),
Table 2. Clinical characteristics and biochemical findings
were similar among the three groups with the exception of
PTH values and femoral neck BMD which were lower in
the (VF−/Fx+) group.
To evaluate possible differences in fracture risk due to dif-
ferent fracture history, we analyzed the number and type of
prevalent non-vertebral fractures in the two groups. Twenty-
four (71%) patients in the (VF+/Fx+) group and 31 (59%)
patients in the (VF−/Fx+) group had only one prevalent non-
vertebral fracture (p = 0.254). The number of patients with hip
fractures did not differ between groups (6 vs 7, respectively).
Similarly, there was no difference between the two groups in
the total number of prevalent non-vertebral fractures, [48/34
(1.4 per patient) vs 76/53 (1.4 per patient)] or major non-
vertebral fractures [34/34 (1.0 per patient) vs 45/53 (0.8 per
patient)].
BMSi and vertebral fractures
BMSi values were similar in the three fracture groups and
significantly lower than those of the non-fracture control
group, Fig. 1. Results remained unchanged after exclusion
of patients with mild (grade 1) vertebral fractures from the
analysis.
We further examined the relationship between BMSi and
the number and severity of vertebral fractures as classified
using Genant’s grading of vertebral fractures. There were 28
patients with 1 vertebral fracture, 9 with two vertebral frac-
tures, and 11 had 3 or more vertebral fractures. There was no
difference in BMSi in patients with 1, 2, or ≥3 vertebral frac-
tures (78.6 ± 0.9, 76.8 ± 1.6, 79.0 ± 1.4; p = 0.555).
Eighteen patients had a grade 1 vertebral fracture as their
highest graded fracture, 20 had grade 2, and 10 had grade 3.
There was no relationship between BMSi values and the se-
verity of vertebral fractures (β = 0.826; p = 0.375).
Discussion
The present study confirms our previous results demonstrating
that BMSi is lower in patients who had sustained one or more
fragility fractures compared to patients who never sustained a
fracture, independently of BMD measurements. It also dem-
onstrates that vertebral fractures are associated with low BMSi
values, which are not further negatively affected by the addi-
tional presence of non-vertebral fractures, including hip frac-
tures. Taken together, these findings suggest that BMSi as
Table 1 Demographic characteristics of 132 patients with low bone
mass
Fracture (n = 101) No fracture (n = 31) p value
Age (years) 63.1 ± 8.9 57.5 ± 9.9 0.004
Male/female 36/65 11/20 0.987
BMI (kg/m2) 24.6 ± 3.5 25.1 ± 4.7 0.475
PTH (pmol/L) 3.6 ± 1.8 3.4 ± 1.4 0.618
Calcium (mmol/L) 2.41 ± 0.09 2.40 ± 0.10 0.784
25-OH D (nmol/L) 66.2 ± 27.1 78.1 ± 30.0 0.080
Creatinine (μmol/L) 73.4 ± 12.3 76.7 ± 15.2 0.228
LS BMD (g/cm2) 0.87 ± 0.12 0.83 ± 0.08 0.090
FN BMD (g/cm2) 0.67 ± 0.08 0.68 ± 0.07 0.672
BMI body mass index, PTH parathyroid hormone, LS lumbar spine, FN
femoral neck, BMD bone mineral density
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measured by IMI on the tibia is associatedwith increased bone
fragility at all relevant skeletal sites.
Our results are in keeping with those of Duarte Sosa et al.
who reported in a preliminary communication that postmeno-
pausal womenwith fractures, including those of the spine, had
significantly lower BMSi values than controls [13]. Our data
are at odds, however, with those of Rudang et al. who reported
no difference in BMSi values between women with and with-
out fractures, and no association between BMSi and vertebral
fractures [12]. Various reasons may be responsible for the
discrepancy in results between the latter study and ours, all
related to major differences in design and methodology.
Firstly, Rudang and colleagues studied elderly women, aged
between 75 and 80 years, who were recruited from a popula-
tion cohort while we included a clinically based cohort of men
and women aged between 40 and 85 years in whom we dem-
onstrated a significant relationship between age and BMSi
values. Secondly, broad inclusion criteria were used in this
study compared to the strict selection criteria for inclusion in
our study, an important prerequisite for studies using new
methodologies. Thirdly, in our study, the presence of fractures
was radiologically confirmed in all patients compared to in-
formation about non-vertebral fractures obtained by question-
naire and not confirmed by review of medical records or ra-
diographs. Finally, subjects with traumatic fractures who were
specifically excluded in our study were included although it is
not yet clear whether such fractures are associated with altered
bone composition. Moreover, in our study, BMSi measure-
ments were performed by a single operator compared to 4
different operators in the study of Rudang and colleagues
leading to the need to adjust their data because of the signif-
icant differences in the results obtained.
It should be also noted that differences in BMSi values
were observed in a study of 42 Norwegian and 46 Spanish
women suggesting possible geographical variations in BMSi
[16]. These differences in BMSi between countries suggest
that, similar to FRAX, normative values for BMSi should
perhaps be developed for different countries to minimize the
implications of these differences in the interpretation of BMSi
results.
Our study has strengths as well as limitations. Of the
strengths of the study is the consecutive inclusion of men
and women aged between 40 and 85 years with low bone
mass attending our outpatient clinic. Although this is a main
strength in our group of patients with fractures, it may be also
perceived as a limitation of our patient control group because
BMD measurements were performed at the discretion of the
patients’ physician. A further strength of our study is that
patients who were currently using or had used bone-
Table 2 Demographic
characteristics of 101 patients
with low bone mass and fragility
fractures
VF+/Fx− (n = 14) VF+/Fx+ (n = 34) VF−/Fx+ (n = 53) p value
Age (years) 64.7 ± 9.3 62.8 ± 9.9 62.8 ± 8.3 0.761
Male/female 8/6 14/20 14/39 0.073
BMI (kg/m2) 25.4 ± 3.1 24.7 ± 3.6 24.3 ± 3.6 0.574
PTH (pmol/L) 4.3 ± 2.0 4.0 ± 1.8 3.2 ± 1.6 0.021
Calcium (mmol/L) 2.39 ± 0.10 2.41 ± 0.11 2.42 ± 0.08 0.657
25-OH D (nmol/L) 64.8 ± 24.6 67.1 ± 28.0 66.0 ± 27.6 0.932
Creatinine (μmol/L) 79.4 ± 10.3 74.3 ± 11.7 71.2 ± 12.8 0.078
LS BMD (g/cm2) 0.86 ± 0.11 0.88 ± 0.16 0.87 ± 0.10 0.833
FN BMD (g/cm2) 0.70 ± 0.09 0.69 ± 0.09 0.65 ± 0.07 0.010a
VF+/Fx− only vertebral fractures, VF+/Fx+ vertebral fractures and non-vertebral fractures, VF−/Fx+ only non-
vertebral fractures, BMI body mass index, PTH parathyroid hormone, LS lumbar spine, FN femoral neck, BMD
bone mineral density
a Post hoc notations FN BMD: VF+/Fx+ vs VF−/Fx+; p = 0.05
Fig. 1 Bone material strength index (BMSi) in patients with only verte-
bral fractures (VF+/Fx−), vertebral fractures and non-vertebral fractures
(VF+/Fx+), only non-vertebral fractures (VF−/Fx+), and in control pa-
tients (VF−/Fx−). Data are shown as box whisker plots. Boxes indicate
median and interquantile range. Bars indicate minimum and maximum
values. Main effect difference: F = 3.74; p = 0.013. Post hoc notations:
VF+/Fx− vs VF−/Fx−; p = 0.004, VF+/Fx+ vs VF−/Fx−;
p = 0.001, VF−/Fx+ vs VF−/Fx−; p < 0.001
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modifying agents were excluded, although this might also
have resulted in the exclusion of patient known to have a high
fracture risk. Of the limitations of our study are its cross-
sectional design and the limited sample size after stratification
for fracture type.
In conclusion, we show that BMSi measured by IMI is low
in patients with fragility fractures regardless of whether this is
a vertebral or a non-vertebral fracture. These data suggest that
BMSi may reflect general bone fragility although this remains
to be established in prospective studies.
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